AstraZeneca: to present advances in haematology
(CercleFinance.com) - AstraZeneca has announced that it will present new clinical data at the European Haematology Association (EHA) Congress, to be held from 8 to 11 June 2023.
The Anglo-Swedish company will present 29 abstracts, 10 of which will be on new drugs, approved or potential, concerning a dozen haematological conditions and rare diseases.
In this context, Alexion, AstraZeneca's rare disease division, will present positive results from a phase III trial evaluating danicopan as an adjunct to standard therapy in patients with paroxysmal nocturnal haemoglobinuria (PNH), a rare and severe blood disorder characterised by the destruction of red blood cells.
AstraZeneca will also present (amongst others) new data analyses for Calquence (acalabrutinib) in patients with chronic lymphocytic leukaemia (CLL) and AZD0486 in patients with relapsed or refractory follicular lymphoma (FL).
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The Anglo-Swedish company will present 29 abstracts, 10 of which will be on new drugs, approved or potential, concerning a dozen haematological conditions and rare diseases.
In this context, Alexion, AstraZeneca's rare disease division, will present positive results from a phase III trial evaluating danicopan as an adjunct to standard therapy in patients with paroxysmal nocturnal haemoglobinuria (PNH), a rare and severe blood disorder characterised by the destruction of red blood cells.
AstraZeneca will also present (amongst others) new data analyses for Calquence (acalabrutinib) in patients with chronic lymphocytic leukaemia (CLL) and AZD0486 in patients with relapsed or refractory follicular lymphoma (FL).
Copyright (c) 2023 CercleFinance.com. All rights reserved.